The first global approval of telotristate Ethyl in the USA has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.

In September 2017, Telotristate Ethyl (Xermelo™), developed by Lexicon Pharmaceuticals, was also approved in all 28 states of the European Union, plus Norway and Iceland for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analog therapy[1].

Kjell Oberg, M.D., Ph.D., Professor of Endocrine Oncology, Chairman Centre of Excellence Endocrine Tumors, Uppsala University Hospital, said that the approval “marks an inflection point for patients and their families in Europe who have waited a long time for a novel treatment option for carcinoid syndrome diarrhoea.” [1]

For further information related to the first approval of telotristate ethyl please visit Drugs,or to learn more about the overall development of telotristate ethyl across all indications visit AdisInsight.

Image credit:  Ivelin Radkov / Fotolia

Leave a Reply